Log In
BCIQ
Print this Print this
 

cariprazine (Vraylar) (MP-214, RGH-188)

  Manage Alerts
Collapse Summary General Information
Company Gedeon Richter Ltd.
DescriptionPartial agonist of the dopamine D3 and D2 receptors
Molecular Target Dopamine D3 receptor (DRD3) ; Dopamine D2 receptor
Mechanism of ActionDopamine D2 receptor agonist; Dopamine D3 receptor agonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$11.0M

$11.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/02/2016

$11.0M

$11.0M

Undisclosed

Get a free BioCentury trial today